Digital Measures for Clinical Trial Endpoints in Huntington's Disease (NCT07010705)
Digital Measures for Clinical Trial Endpoints in Huntington's Disease (MEND-HD)
🩺 Plain-English Summary (8th-Grade Level)
MEND-HD is a longitudinal study evaluating the feasibility of passive monitoring of gait and chorea in patients with HD and the meaningfulness of these outcomes for patients with HD and their care partners/support persons. Participants will take part in four virtual visits with study investigators to answer survey questions on movement and cognition, perform in-home movement assessments, and take part in an interview regarding the meaningfulness of gait and chorea in their daily lives. Participant and care partner interviews will be used for symptom mapping and qualitative data analysis to assess the relevance and impact of the targeted symptoms on the participant's daily life. The study may be extended to 3 years to include yearly visits.
Who can join: Review the eligibility criteria below.
Location: University of Rochester Medical Center — Rochester, New York
Age range: 25 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- University of Rochester Medical Center — Rochester, New York
📞 Contact the Study Coordinator
Phone: (585) 704-0344
Email: Sugi_maheswaran@urmc.rochester.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Huntington Disease
- Neurobiological Predictors of Huntington's Disease (PREDICT-HD) — Iowa City, Iowa
- Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease — Nashville, Tennessee
- GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease — Birmingham, Alabama
- An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD) — Clayton,
- Modification of Threat Interpretation Bias to Reduce Anxiety in Neurodegenerative Movement Disorders (Aim 3) — Charlottesville, Virginia
- Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease — Rochester, New York
Explore by condition: All Huntington Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.